Animal models of neuropathic pain

Fundamental and Clinical Pharmacology

Volumn 25, Issue 1, 2011, Pages 1-28

  Jaggi, Amteshwar Singh ^a   Jain, Vivek ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Anti cancer agents; Cancer pain; Central pain; HIV; Neuropathic pain; Peripheral neuropathy; Post herpetic neuralgia; Trigeminal neuralgia

Indexed keywords

ANIMAL MODEL; CANCER PAIN; DIABETIC NEUROPATHY; METHODOLOGY; NERVE FIBER TRANSECTION; NERVE LIGATION; NEURITIS; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NERVE INJURY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SCIATIC NERVE; TRIGEMINUS NEURALGIA;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURALGIA;

EID: 78650934325     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00801.x     Document Type: Review

References (303)

1. Mitchell S.W. Injuries of nerves and their consequences, JB Lippincott, Philadephia, 1872.
2. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet (1999) 353 1959-1964.
3. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain. (2002) 18 350-354.
4. Werhagen L., Budh C.N., Hultling C., Molander C. Neuropathic pain after traumatic spinal cord injury relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord (2004) 42 665-673.
5. Perkins F.M., Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology (2000) 93 1123-1133.
6. D'Amour F.E., Smith D.L. A method for determining the loss of pain sensation. J. Pharmacol. Exp. Ther. (1941) 72 74-79.
7. Woolfe G., MacDonald A.D. The evaluation of the analgesic action of pethidine hydrochloride (demerol). J. Pharmacol. Ther. (1944) 80 300-307.
8. Wall P.D., Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature (1974) 248 740-743.
9. Wall P.D., Devor M., Inbal R. et al. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain (1979) 7 103-113.
10. Devor M., Wall P.D. Type of sensory nerve fibre sprouting to form a neuroma. Nature (1976) 262 705-708.
11. Amir R., Devor M. Ongoing activity in neuroma afferents bearing retrograde sprouts. Brain Res. (1993) 630 283-288.
12. Muthuraman A., Diwan V., Jaggi A.S., Singh N., Singh D. Ameliorative effects of Ocimum sanctum in sciatic nerve transection-induced neuropathy in rats. J. Ethnopharmacol. (2008) 120 56-62.
13. Wall P.D., Scadding J.W., Tonikiewicz M.M. The production and prevention of experimental anesthesia dolorosa. Pain (1979) 6 175-182.
14. Zeltser R., Beilin B., Zaslansky R., Seltzer Z. Comparison of autotomy behavior induced in rats by various clinically used neurectomy methods. Pain (2000) 89 19-24.
15. Kauppila T. Correlation between autotomy-behavior and current theories of neuropathic pain. Neurosci. Biobehav. Rev. (1998) 23 111-129.
16. Riopelle J.M. The ethics of using animal models to study treatment of phantom pain. Anesthesiology (1992) 76 1069-1071.
17. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain (1988) 33 87-107.
18. Muthuraman A., Jaggi A.S., Singh N., Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine-induced painful neuropathy in rats. Eur. J. Pharmacol. (2008) 587 104-111.
19. Martucci C., Trovato A.E., Costa B. et al. The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain (2008) 137 81-95.
20. Sacerdote P., Franchi S., Trovato A.E., Valsecchi A.E., Panerai A.E., Colleoni M. Transient early expression of TNF-α sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci. Lett. (2008) 436 210-213.
21. De Vry J., Kuhl E., Franken-Kunkel P., Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. (2004) 491 137-148.
22. Dowdall T., Robinson I., Meert T.F. Comparison of five different rat models of peripheral nerve injury. Pharmacol. Biochem. Behav. (2005) 80 93-108.
23. Carlton S.M., Dougherty P.M., Pover C.M., Coggeshall R.E. Neuroma formation and numbers of axons in a rat model of experimental peripheral neuropathy. Neurosci. Lett. (1991) 131 88-92.
24. Gabay E., Tal M. Pain behavior and nerve electrophysiology in the CCI model of neuropathic pain. Pain (2004) 110 354-360.
25. Nakamura S., Atsuta Y. The effects of experimental neurolysis on ectopic firing in a rat chronic constriction nerve injury model. J. Hand Surg. Am. (2006) 31 35-39.
26. Ro L.S., Jacobs J.M. The role of the saphenous nerve in experimental sciatic nerve mononeuropathy produced by loose ligatures: a behavioural study. Pain (1993) 52 359-369.
27. Maves T.J., Pechman P.S., Gebhart G.F., Meller S.T. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain (1993) 54 57-69.
28. Seltzer Z., Dubner R., Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain (1990) 43 205-218.
29. Kim K.J., Yoon Y.W., Chung J.M. Comparison of three rodent neuropathic pain models. Exp. Brain Res. (1997) 113 200-206.
30. Xu M., Bruchas M.R., Ippolito D.L., Gendron L., Chavkin C. Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by μ opioid activation of p38mitogen-activated protein kinase. J. Neurosci. (2007) 27 2570-2581.
31. Mitchell V.A., White D.M., Cousins M.J. The long-term effect of epidural administration of butamben suspension on nerve injury-induced allodynia in rats. Anesth. Analg. (1999) 89 989-994.
32. Malmberg A.B., Basbaum A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain (1998) 76 215-222.
33. Yoon Y.W., Lee D.H., Lee B.H., Chung K., Chung J.M. Different strains of rats show different levels of neuropathic pain behaviors. Exp. Brain Res. (1999) 129 167-171.
34. Bennett G.J. An animal model of neuropathic pain: a review. Muscle Nerve (1993) 16 1040-1048.
35. Seltzer Z. The relevance of animal neuropathy models for chronic pain in humans. Sem. Neurosci. (1995) 7 211-219.
36. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 50 355-363.
37. Komori N., Takemori N., Kim H.K. et al. Proteomics study of neuropathic and non-neuropathic dorsal root ganglia: altered protein regulation following segmental spinal nerve ligation injury. Physiol. Genomics (2007) 29 215-230.
38. Lin C.S., Tsaur M.L., Chen C.C. et al. Chronic intrathecal infusion of minocycline prevents the development of spinal-nerve ligation-induced pain in rats. Reg. Anesth. Pain Med. (2007) 32 209-216.
39. Choi Y., Yoon Y.W., Na H.S., Kim S.H., Chung J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain (1994) 59 369-376.
40. LaBuda C.J., Little P.J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J. Neurosci. Methods (2005) 144 175-181.
41. Kinnman E., Levine J.D. Sensory and sympathetic contributions to nerve injury-induced sensory abnormalities in the rat. Neuroscience (1995) 64 751-767.
42. Xie J., Yoon Y.W., Yom S.S., Chung J.M. Norepinephrine rekindles mechanical allodynia in sympathectomized neuropathic rat. Analgesia (1995) 1 107-113.
43. Lee B.H., Yoon Y.W., Chung K., Chung J.M. Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. Exp. Brain Res. (1998) 120 432-438.
44. Carlton S.M., Lekan H.A., Kim S.H., Chung J.M. Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain (1994) 56 155-166.
45. Decosterd I., Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain (2000) 87 149-158.
46. Bourquin A.F., Süveges M., Pertin M. et al. Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. Pain (2006) 122 14.e1-14.e14.
47. Kohno T., Moore K.A., Baba H., Woolf C.J. Peripheral nerve injury alters excitatory synaptic transmission in lamina II of the rat dorsal horn. J. Physiol. (2003) 548 131-138.
48. Baliki M., Calvo O., Chialvo D.R., Apkarian A.V. Spared nerve injury rats exhibit thermal hyperalgesia on an automated operant dynamic thermal escape Task. Mol. Pain (2005) 1 18.
49. Pertin M., Allchorne A.J., Beggah A.T., Woolf C.J., Decosterd I. Delayed sympathetic dependence in the spared nerve injury (SNI) model of neuropathic pain. Mol. Pain (2007) 3 21.
50. Shields S.D., Eckert W.A., Basbaum A.I. Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis. J. Pain (2003) 4 465-470.
51. Gong-ming W., Yu-ke T., Jian-ping C. et al. Evaluation of NR2B peptide as subunit vaccines against experimental neuropathic pain. Chin. Med. J. (2007) 120 643-647.
52. Lindia J.A., Köhler M.G., Martin W.J., Abbadie C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain (2005) 117 145-153.
53. Lee B.H., Won R., Baik E.J., Lee S.H., Moon C.H. An animal model of neuropathic pain employing injury to the sciatic nerve branches. Neuroreport (2000) 11 657-661.
54. Jain V., Jaggi A.S., Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol. Res. (2009) 59 385-392.
55. Dowdall T., Meert T.F. Behavioral evaluation of symptoms of allodynia and hyperalgesia in rats with a tibial and sural nerve transection. J. Neuropathic Pain Symptom Palliation (2005) 1 29-37.
56. Han D.W., Kweon T.D., Kim K.J., Lee J.S., Chang C.H., Lee Y.W. Does the tibial and sural nerve transection model represent sympathetically independent pain? Yonsei Med. J. (2006) 47 847-851.
57. Vadakkan K.I., Jia Y.H., Zhuo M. A behavioral model of neuropathic pain induced by ligation of the common peroneal nerve in mice. J. Pain (2005) 6 747-756.
58. Wagner R., DeLeo J.A., Coombs D.W., Willenbring S., Fromm C. Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model. Brain Res. (1993) 629 323-326.
59. DeLeo J.A., Coombs D.W., Willenbring S. et al. Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain (1994) 56 9-16.
60. Colburn R.W., Rickman A.J., DeLeo J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. (1999) 157 289-304.
61. Willenbring S., Beauprie I.G., DeLeo J.A. Sciatic cryoneurolysis in rats: a model of sympathetically independent pain. Part 1: effects of sympathectomy. Anesth. Analg. (1995) 81 544-548.
62. Willenbring S., DeLeo J.A., Coombs D.W. Sciatic cryoneurolysis in rats: a model of sympathetically independent pain. Part 2: adrenergic pharmacology. Anesth. Analg. (1995) 81 549-554.
63. Na H.S., Han J.S., Ko K.H., Hong S.K. A behavioral model for peripheral neuropathy produced in rat's tail by inferior caudal trunk injury. Neurosci. Lett. (1994) 177 50-52.
64. Sung B., Na H.S., Kim Y.I. et al. Supraspinal involvement in the production of mechanical allodynia by spinal nerve injury in rats. Neurosci. Lett. (1998) 246 117-119.
65. Back S.K., Lee J., Hong S.K., Na H.S. Loss of spinal l-opioid receptor is associated with mechanical allodynia in a rat model of peripheral neuropathy. Pain (2006) 123 117-126.
66. Back S.K., Kim J.S., Hong S.K., Na H.S. Ascending pathways for mechanical allodynia in a rat model of neuropathic pain. Neuroreport (2003) 14 1623-1626.
67. Sung B., Loh H.H., Wei L.-N. Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury. Neurosci. Lett. (2000) 291 163-166.
68. Back S.K., Sung B., Hong S.K., Na H.S. A mouse model for peripheral neuropathy produced by a partial injury of the nerve supplying the tail. Neurosci. Lett. (2002) 322 153-156.
69. Said G., Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res. Immunol. (1992) 143 589-599.
70. Chacur M., Milligan E.D., Gazda L.S. et al. A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain (2001) 94 231-244.
71. Gazda L.S., Milligan E.D., Hansen M.K. et al. Sciatic inflammatory neuritis (SIN): behavioral allodynia is paralleled by peri-sciatic proinflammatory cytokine and superoxide production. J. Peripher. Nerv. Syst. (2001) 6 111-129.
72. Wagner R., Myers R.R. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport. (1996) 7 2897-2901.
73. Wang H., Bloom O., Zhang M. et al. HMG-1 as a later mediator of endotoxin lethality in mice. Science (1999) 285 248-251.
74. Eliav E., Herzberg U., Ruda M.A., Bennett G.J. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain (1999) 83 169-182.
75. Maleki J., LeBel A.A., Bennett G.J., Schwartzman R.J. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain (2000) 88 259-266.
76. Shir Y., Seltzer Z. Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats. Pain (1991) 45 309-320.
77. Woda A., Pionchon P. A unified concept of idiopathic orofacial pain: pathophysiologic features. J. Orofac. Pain (2000) 14 196-212.
78. Mosconi T., Kruger L. Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain (1996) 64 37-57.
79. Pitcher G.M., Ritchie J., Henry J.L. Nerve constriction in the rat: model of neuropathic, surgical and central pain. Pain (1999) 83 37-46.
80. Coull J.A., Boudreau D., Bachand K. et al. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature (2003) 424 938-942.
81. Benbouzid M., Pallage V., Rajalu M. et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur. J. Pain (2008) 12 591-599.
82. Benbouzid M., Gavériaux-Ruff C., Yalcin I. et al. Delta-opioid receptors are critical for tricylic antidepressant treatment of neuropathic allodynia. Biol. Psychiatry (2008) 63 633-636.
83. Coull J.A., Beggs S., Boudreau D. et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature (2005) 438 1017-1021.
84. Yalcin I., Choucair-Jaafar N., Benbouzid M. et al. Beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. (2009) 65 218-225.
85. Gazelius B., Cui J.G., Svensson M., Meyerson B., Linderoth B. Photochemically induced ischaemic lesion of the rat sciatic nerve. A novel method providing high incidence of mononeuropathy. Neuroreport (1996) 7 2619-2623.
86. Kupers R., Yu W., Persson J.K.E., Xu X.J., Wiesenfeld-Hallin Z. Photochemically-induced ischemia of the rat sciatic nerve produces a dose-dependent and highly reproducible mechanical, heat and cold allodynia, and signs of spontaneous pain. Pain (1998) 76 45-59.
87. Hao J.X., Blakeman K.H., Yu W., Hultenby K., Xu X.J., Wiesenfeld-Hallin Z. Development of a mouse model of neuropathic pain following photochemically induced ischemia in the sciatic nerve. Exp. Neurol. (2000) 163 231-238.
88. Myers R.R., James H.E., Powell H.C. Laser injury of peripheral nerve: a model for focal endoneurial damage. J. Neurol. Neurosurg. Psychiatry (1985) 48 1265-1268.
89. Chiang H.Y., Chen C.T., Chien H.F., Hsieh S.T. Skin denervation, neuropathology, and neuropathic pain in a laser-induced focal neuropathy. Neurobiol. Dis. (2005) 18 40-53.
90. Allen A.R. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column, J. Am. Med. Assoc. (1911) 57 878-890.
91. Hao J.X., Xu X.J., Aldskogius H., Seiger A., Wiesenfeld-Hallin Z. Allodynia-like effects in rat after ischemic spinal cord injury photochemically induced by laser irradiation. Pain (1991) 45 175-185.
92. Christensen M.D., Everhart A.W., Pickelman J., Hulsebosch C.E. Mechanical and thermal allodynia in chronic central pain following spinal cord injury. Pain (1996) 68 97-107.
93. Hulsebosch C.E., Xu G.Y., Perez-Polo J.R., Westlund K.N., Taylor C.P., McAdoo D.J. Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. J. Neurotrauma (2000) 17 1205-1217.
94. Yezierski R.P., Liu S., Ruenes G.L., Kajander K.J., Brewer K.L. Intraspinal injections of the AMPA-metabotropic receptor agonist QUIS resulted in neuronal loss, cavity formation, astrocytic scarring, and a prominent inflammatory reaction. Pain (1998) 75 141-155.
95. Greenberg J., McKeever P.E., Balentine J.D. Lysosomal activity in experimental spinal cord trauma: an ultrastructural cytochemical evaluation. Surg. Neurol. (1978) 9 361-364.
96. Anderson T.E. A controlled pneumatic technique for experimental spinal cord contusion. J. Neurosci. Methods (1982) 6 327-333.
97. Siddall P.J., Taylor D.A., McClelland J.M., Rutkowski S.B., Cousins M.J. Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury. Pain (1999) 81 187-197.
98. Siddall P.J., Xu C.L., Cousins M.J. Allodynia following traumatic spinal cord injury in the rat. Neuroreport (1995) 6 1241-1244.
99. Drew G.M., Siddall P.J., Duggan A.W. Responses of spinal neurons to cutaneous and dorsal root stimuli in rats with mechanical allodynia after contusive spinal cord injury. Brain Res. (2001) 893 59-69.
100. Genovese T., Esposito E., Mazzon E. et al. Effect of cyclopentanone prostaglandin 15-deoxy-delta12, 14pgj2 on early functional recovery from experimental spinal cord injury. Shock (2008) 30 142-152.
101. Liu D., Thangnipon W., McAdoo D.J. Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res. (1991) 547 344-348.
102. Simpson R.K. Jr, Robertson C.S., Goodman J.C. Spinal cord ischemia-induced elevation of amino acids: extracellular measurements with microdialysis. (Neurochem. Res. (1990) 15 635-639.
103. Bunge M.B., Holets V.R., Bates M.L., Clarke T.S., Watson B.D. Characterization of photochemically induced spinal cord injury in the rat by light and electron microscopy. Exp. Neurol. (1994) 127 76-93.
104. Basso D.M. Beattie M.S., Bresnahan J.C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight drop device versus transection. Exp. Neurol. (1996) 139 244-256.
105. Yezierski R.P., Santana M., Park S.H., Madsen P.W. Neuronal degeneration and spinal cavitation following intraspinal injections of quisqualic acid in the rat. J. Neurotrauma (1993) 10 445-456.
106. Madsen P.W., Yezierski R.P., Holets V.R. Syringomyelia: clinical observations and experimental studies. J. Neurotrauma (1994) 11 241-254.
107. Yezierski R.P., Park S.H. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci. Lett. (1993) 157 115-119.
108. Liu X.Z., Xu X.M., Hu R. et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. (1997) 17 5395-5406.
109. Wilcox G.L. Pharmacological studies of grooming and scratching behavior elicited by spinal substance P and excitatory amino acids. Ann. NY Acad. Sci. (1988) 525 228-236.
110. Aanonsen L.M., Wilcox G.L. Muscimol, gamma-aminobutyric acid A receptors and excitatory amino acids in the mouse spinal cord. J. Pharmacol. Exp. Ther. (1989) 248 1034-1038.
111. Fairbanks C.A., Schreiber K.L., Brewer K.L. et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. (2000) 97 10584-10589.
112. Watson B.D., Prado R., Dietrich W.D., Ginsberg M.D., Green B.A. Photochemically induced spinal cord injury in the rat. Brain Res. (1986) 367 296-300.
113. Prado R., Dietrich W.D., Watson B.D., Ginsberg M.D., Green B.A. Photochemically induced graded spinal cord infarction. Behavioral, electrophysiological, and morphological correlates. J. Neurosurg. (1987) 67 745-753.
114. Xu X.J., Hao J.X., Aldskogius H., Seiger A., Wiesenfeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain (1992) 48 279-290.
115. Hao J.X., Xu X.J., Aldskogius H., Seiger A., Wiesenfeld-Hallin Z. Photochemically induced transient spinal ischemia induces behavioral hypersensitivity to mechanical and cold stimuli, but not to noxious-heat stimuli, in the rat. Exp. Neurol. (1992) 118 187-194.
116. Kim J., Yoon Y.W., Hong S.K., Na H.S. Cold and mechanical allodynia in both hind paws and tail following thoracic spinal cord hemisection in rats: time courses and their correlates. Neurosci. Lett. (2003) 343 200-204.
117. Koehler P.J., Endtz L.J. The Brown-Sequard sundrome. Arch. Neurol. (1986) 43 921-924.
118. Ito T., Mochida A., Saito K. et al. An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years. Nihon Kokyuki Gakkai Zasshi (2002) 40 71-76.
119. Pal P.K. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr. Clin. Neurophysiol. (1999) 39 323-330.
120. McCarthy G.M., Skillings J.R. Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer. Oral Surg. Oral Med. Oral Pathol. (1992) 74 299-304.
121. Jackson D.V. Jr, Sethi V.S., Spurr C.L., McWhorter J.M. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res. (1981) 41 1466-1468.
122. Tanner K., Levine J., Topp K. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine induced painful neuropathy in rat. J. Comp. Neurol. (1998) 395 481-492.
123. Topp K.S., Tanner K.D., Levine J.D. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine induced painful peripheral neuropathy in the rat. J. Comp. Neurol. (2000) 424 563-576.
124. Tanner K.D., Reichling D.B., Levine J.D. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J. Neurosci. (1998) 18 6480-6491.
125. Gottschalk P.G., Dyck P.J., Kiely J.M. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology (1968) 18 875-882.
126. Todd G.C., Gibson W.R., Morton D.M. Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats and dogs. J. Toxicol. Environ. Health (1976) 1 843-850.
127. Todd G.C., Griffing W.J., Gibson W.R., Morton D.M. Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids. Cancer Treat. Rep. (1979) 63 35-41.
128. Aley K.O., Reichling D.B., Levine J.D. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience (1996) 73 259-265.
129. Sweitzer S.M., Pahl J.L., DeLeo J.A. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci. Lett. (2006) 400 258-261.
130. Authier N., Coudore F., Eschalier A., Fialip J. Pain related behavior during vincristine-induced neuropathy in rats. Neuroreport (1999) 10 965-968.
131. Authier N., Gillet J.P., Fialip J., Eschalier A., Coudore F. A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology (2003) 24 797-805.
132. Aley K.O., Levine J.D. Different peripheral mechanisms mediate enhanced nociception in metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience (2002) 111 389-397.
133. Joseph E.K., Levine J.D. Sexual dimorphism for protein kinase c epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience (2003) 119 831-838.
134. Lynch J.J. III, Wade C.L., Zhong C.M., Mikusa J.P., Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain (2004) 110 56-63.
135. Siau C., Bennett G.J. Dysregulation of neuronal calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth. Analg. (2006) 102 1485-1490.
136. Xiao W., Boroujerdi A., Bennett G.J., Luo Z.D. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience (2007) 144 714-720.
137. Xiao W.H., Bennett G.J. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine. Pain (2007) 135 262-270.
138. Boyle F.M., Wheeler H.R., Shenfield G.M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Ther. (1996) 279 410-415.
139. Ja'afer F.M., Hamdan F.B., Mohammed F.H. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp. Brain Res. (2006) 173 334-345.
140. Norido F., Finesso M., Fiorito C. et al. General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in the rabbit. Toxicol. Appl. Pharmacol. (1988) 93 433-441.
141. Fiori M.G., Schiavinato A., Lini E., Nunzi M.G. Peripheral neuropathy induced by intravenous administration of vincristine sulfate in the rabbit. An ultra structure study. Toxicol. Pathol. (1995) 23 248-255.
142. Ogawa T., Mimura Y., Kato H., Ootsubo S., Murokoshi M. The usefulness of rabbit as an animal model for the neuropathological assessment of neurotoxicity following the administration of vincristine. Neurotoxicology (2000) 21 501-512.
143. Contreras P.C., Vaught J.L., Gruner J.A. et al. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res. (1997) 774 20-26.
144. Bardos G., Moricz K., Jaszlits L. et al. BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats. Toxicol. Appl. Pharmacol. (2003) 190 9-16.
145. Vera G., Chiarlone A., Cabezos P.A., Pascual D., Martín M.I., Abalo R. WIN 55, 212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci. (2007) 81 468-479.
146. Chaudhry V., Chaudhry M., Crawford T.O., Simmons-O'Brien E., Griffin J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology (2003) 60 337-340.
147. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin. Drug Saf. (2003) 2 597-607.
148. Koning D.P., Neijt J.P., Jennekens F.G.I., Gispen W.H. Evaluation of cis-di ammine dichloro platinum (II) (Cisplatin) neurotoxicity in rats. Toxicol. Appl. Pharmacol. (1987) 89 81-87.
149. Cece R., Petruccioli M.G., Cavaletti G., Barajon I., Tredici G. An ultra structural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol. Histopathol. (1995) 10 837-845.
150. Cece R., Petruccioli M.G., Pizzini G., Cavaletti G., Tredici G. Ultra structural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J. Submicrosc. Cytol. Pathol. (1995) 27 417-425.
151. Meijer C., De Vries E.G., Marmiroli P., Tredici G., Frattola L., Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology (1999) 20 883-887.
152. Tredici G., Braga M., Nicolini G. et al. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol. (1999) 159 551-558.
153. Tredici G., Tredici S., Fabbrica D., Minoia C., Cavaletti G. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J. Neurooncol. (1998) 36 31-40.
154. Boyle F.M., Wheeler H.R., Shenfield G.M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J. Neurooncol. (1999) 41 107-116.
155. Authier N., Gillet J.P., Fialip J., Eschalier A., Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp. Neurol. (2003) 182 12-20.
156. Bianchi R., Gilardini A., Rodriguez-Menendez V. et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur. J. Cancer (2007) 43 710-717.
157. Apfel S.C., Arezzo J.C., Lipson L., Kessler J.A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. (1992) 31 76-80.
158. Szilvassy J., Sziklai I., Racz T., Horvath P., Rabloczky G., Szilvassy Z. Impaired bronchomotor responses to field stimulation in guinea-pigs with cisplatin-induced neuropathy. Eur. J. Pharmacol. (2000) 403 259-265.
159. Cavaletti G., Tredici G., Marmiroli P., Petruccioli M.G., Barajon I., Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta. Neuropathol. (Berl.), (1992) 84 364-371.
160. Gregg R.W., Molepo J.M., Monpetit V.J. et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol., (1992) 10 795-803.
161. Authier N., Fialip J., Eschalier A., Coudore F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci. Lett. (2000) 291 73-76.
162. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. (2003) 30 5-13.
163. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann. Pharmacother. (2005) 39 128-135.
164. Cavaletti G., Marmiroli P., Rigolio R. et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res. (2002) 22 4199-4204.
165. Cavaletti G., Tredici G., Petruccioli M.G. et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer (2001) 37 2457-2463.
166. Jamieson S.M., Liu J., Connor B., McKeage M.J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother. Pharmacol. (2005) 56 391-399.
167. Ghirardi O., Lo Giudice P., Pisano C. et al. Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. (2005) 25 2681-2687.
168. Ling B., Authier N., Balayssac D., Eschalier A., Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain (2007) 128 225-234.
169. Ling B., Coudor'e-Civiale M.A., Balayssac D., Eschalier A., Coudore F., Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology (2007) 234 176-184.
170. Dougherty P.M., Cata J.P., Cordella J.V., Burton A., Weng H.R. Taxol induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain (2004) 109 132-142.
171. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule stabilizing agents. J. Clin. Oncol. (2006) 24 1633-1642.
172. Mielke S., Sparreboom A., Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur. J. Cancer (2006) 42 24-30.
173. Persohn E., Canta A., Schoepfer S. et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur. J. Cancer (2005) 41 1460-1466.
174. Cavaletti G., Bogliun G., Marzorati L. et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 75 1141-1150.
175. Polomanoa R.C., Mannes A.J., Clark U.S., Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain (2001) 94 293-304.
176. Flatters S.J.L., Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain (2006) 122 247-257.
177. Ledeboer A., Jekich B.M., Sloane E.M. et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and pro-inflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. (2007) 21 686-698.
178. Kilpatrick T.J., Phan S., Reardon K., Lopes E.C., Cheema S.S. Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res. (2001) 911 163-167.
179. Authier N., Gillet J.P., Fialip J., Eschalier A., Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res. (2000) 887 239-249.
180. Cliffer K.D., Siuciak J.A., Carson S.R. et al. Physiological characterization of Taxol induced large-fiber sensory neuropathy in the rat. Ann. Neurol. (1998) 43 46-55.
181. Peters C.M., Jimenez-Andrade J.M., Jonas B.M. et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp. Neurol. (2007) 203 42-54.
182. Dina O.A., Chen X., Reichling D., Levine J.D. Role of protine kinase cepsilon and protine kinase A in a model of paclitaxel-induced painful perioheral neuropathy in the rat. Neuroscience (2001) 108 507-515.
183. Roglio I., Bianchi R., Camozzi F. et al. Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J. Peripher. Nerv. Syst. (2009) 14 36-44.
184. Pardo C.A., McArthur J.C., Griffin J.W. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J. Peripher. Nerv. Syst. (2001) 6 21-27.
185. Keswani S.C., Pardo C.A., Cherry C.L., Hoke A., McArthur J.C. HIV-associated sensory neuropathies. AIDS (2002) 16 2105-2117.
186. Bhangoo S.K., Ren D., Miller R.J. et al. CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav. Immun. (2007) 21 581-591.
187. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J.Peripher. Neurol. (2001) 6 14-20.
188. Anderson T.D., Davidovich A., Arceo R., Brosnan C., Arezzo J., Schaumburg H.H. Peripheral neuropathy induced by 2, 3-dideoxycytidine. A rabbit model of 2, 3-dideoxycytidine neurotoxicity. Lab. Invest. (1991) 66 63-74.
189. Schmued L.C., Albertson C.M., Andrews A., Sandberg J.A., Nickols J., Slikker W. Jr. Evaluation of brain and nerve pathology in rats chronically dosed with ddI or isoniazid. Neurotoxicol. Teratol. (1996) 18 555-563.
190. Patterson T.A., Schmued L.C., Sandberg J.A., Slikker W. Jr. Temporal development of 2, 3-dideoxyinosine (ddI)-induced peripheral myelinopathy. Neurotoxicol. Teratol. (2000) 22 429-434.
191. Joseph E.K., Chen X., Khasar S.G., Levine J.D. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain (2004) 107 147-158.
192. Cooley T.P., Kunches L.M., Saunders C.A. et al. Treatment of AIDS and AIDS-related complex with 2, 3dideoxyinosine given once daily. Rev. Infect. Dis. (1990) 12 S552-S560.
193. Calcutt N.A. Potential mechanisms of neuropathic pain in diabetes. Int. Rev. Neurobiol. (2002) 50 205-228.
194. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain (1993) 53 81-88.
195. Lee J., Cox D., Mook D., McCarty R. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Pain (1990) 40 105-107.
196. Burchiel K.J., Russell L.C., Lee R.P., Sima A.A. Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes (1985) 34 1210-1213.
197. Ahlgren S., Levine J. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience (1993) 52 1049-1055.
198. ATP channels in reduced antinociceptive effect of morphine in streptozotocin-induced diabetic mice. Indian J. Exp. Biol. (2000) 38 447-451.
199. Grover V.S., Sharma A., Singh M. Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur. J. Pharmacol. (2000) 399 161-164.
200. Khan N., Bakshi K.S., Jaggi A.S., Singh N. Ameliorative potential of spironolactone in diabetes induced hyperalgesia in mice. Yakugaku Zasshi (2009) 129 593-599.
201. Khan N., Singh N., Jaggi A.S. Possible role of spleen-derived factors, vanilloid receptors and calcitonin gene-related peptide in diabetes induced hyperalgesia in mice. Yakugaku Zasshi (2008) 128 1699-1705.
202. Anjaneyulu M., Chopra K. Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27 1001-1005.
203. Aley K.O., Levine J.D. Rapid onset pain induced by intravenous Streptozotocin in the rat. J. Pain (2001) 2 146-150.
204. Goto Y., Suzuki K., Ono T., Sasaki M., Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv. Exp. Med. Biol. (1988) 246 29-31.
205. Bisbis S., Bailbe D., Tormo M.A. et al. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am. J. Physiol. (1993) 265 E807-E813.
206. O'Rourke C.M., Davis J.A., Saltiel A.R., Cornicelli J.A. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism (1997) 46 192-198.
207. Suzuki K., Yen-Chung H., Toyota T., Goto Y., Hirata Y., Okada K. The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats. Diabetes Res. (1990) 14 21-25.
208. Wada R., Koyama M., Mizukami H., Odaka H., Ikeda H., Yagihashi S. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab. Res. Rev. (1999) 15 332-337.
209. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. (2005) 76 2655-2668.
210. Li F., Abatan O.I., Kim H. et al. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol. Dis. (2006) 22 669-676.
211. Murakawa Y., Zhang W., Pierson C.R. et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab. Res. Rev. (2002) 18 473-483.
212. Oltman C.L., Coppey L.J., Gellett J.S., Davidson E.P., Lund D.D., Yorek M.A. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am. J. Physiol. Endocrinol. Metab. (2005) 289 E113-E122.
213. Sima A.A., Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann. N Y Acad. Sci. (2006) 1084 235-249.
214. Schmidt R.E., Dorsey D.A., Beaudet L.N., Parvin C.A., Zhang W., Sima A.A. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J. Neuropathol. Exp. Neurol. (2004) 63 450-460.
215. Underwood R.A., Gibran N.S., Muffley L.A., Usui M.L., Olerud J.E. Color subtractive-computer-assisted image analysis for quantification of cutaneous nerves in a diabetic mouse model. J. Histochem. Cytochem. (2001) 49 1285-1291.
216. Norido F., Canella R., Zanoni R., Gorio A. Development of diabetic neuropathy in the C57BL/Ks (db/db) mouse and its treatment with gangliosides. Exp. Neurol. (1984) 83 221-232.
217. Coleman D.L.. Diabetes-obesity syndromes in mice. Diabetes. (1982) 31 (Suppl. 1) 1-6.
218. Houseknecht K.L., Portocarrero C.P. Leptin and its receptors: regulators of whole-body energy homeostasis. Domest. Anim. Endocrinol. (1998) 15 457-475.
219. Drel V.R., Mashtalir N., Ilnytska O. et al. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of Type 2 diabetes and obesity. Diabetes (2006) 55 3335-3343.
220. Muller K.A., Ryals J.M., Feldman E.L., Wright D.E. Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes (2008) 57 1693-1701.
221. Kamiya H., Murakawa Y., Zhang W., Sima A.A.F. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab. Res. Rev. (2005) 21 448-458.
222. Dyck P.J., Dyck P.J., Larson T.S., O'Brien P.C., Velosa J.A. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts: Nerve Growth Factor Study Group. Diabetes Care (2000) 23 510-517.
223. Obrosova I.G., Mabley J.G., Zsengellér Z. et al. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J. (2005) 19 401-403.
224. Gabra B.H., Sirois P. Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor. Eur. J. Pharmacol. (2005) 514 61-67.
225. Kamiya H., Zhang W., Ekberg K., Wahren J., Sima A.A. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes (2006) 55 3581-3587.
226. Zhang W., Murakawa Y., Wozniak K.M., Slusher B., Sima A.A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J. Neurol. Sci. (2006) 247 217-223.
227. Zhang W., Murakawa Y., Wozniak K.M., Slusher B., Sima A.A.F. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB-Wor-rat. J. Neurol. Sci. (2002) 194 21-28.
228. Menendez L., Lastra A., Fresno M.F. et al. Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res. (2003) 969 102-109.
229. Menendez L., Lastra A., Hidalgo A., Meana A., Garcia E., Baamonde A. Peripheral opioids act as analgesics in bone cancer pain in mice. Neuroreport (2003) 14 867-869.
230. Schwei M.J., Honore P., Rogers S.D. et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci. (1999) 19 10886-10897.
231. Wacnik P.W., Eikmeier L.J., Ruggles T.R. et al. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J. Neurosci. (2001) 21 9355-9366.
232. Shimoyama M., Tanaka K., Hasue F., Shimoyama N. A mouse model of neuropathic cancer pain. Pain (2002) 99 167-174.
233. Sasamura T., Nakamura S., Iida Y. et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur. J. Pharmacol. (2002) 441 185-191.
234. Mantyh P.W. A mechanism-based understanding of bone cancer pain. Novartis Found. Symp. (2004) 261 194-214.
235. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain (1997) 69 1-18.
236. Vermeirsch H., Nuydens R., Salmon P., Meert T. Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol. Biochem. Behav. (2004) 79 243-251.
237. Hald A., Nedergaard S., Hansen R.R., Ding M., Heegaard A.M. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur. J. Pain (2009) 13 138-145.
238. Niiyama Y., Kawamata T., Yamamoto J., Furuse S., Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br. J. Anaesth. (2009) 102 251-258.
239. Honore P., Rogers S.D., Schwei M.J. et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience (2000) 98 585-598.
240. Honoré P., Schwei J., Rogers S.D. et al. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog. Brain Res. (2000) 129 389-397.
241. Khasabova I.A., Khasabov S.G., Harding-Rose C. et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J. Neurosci. (2008) 28 11141-11152.
242. Simone D.A., Khasabov S.G., Hamamoto D.T. Changes in response properties of nociceptive dorsal horn neurons in a murine model of cancer pain. Sheng Li Xue Bao (2008) 60 635-644.
243. Cain D.M., Wacnik P.W., Turner M. et al. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J. Neurosci. (2001) 21 9367-9376.
244. Medhurst S.J., Walker K., Bowes M. et al. A rat model of bone cancer pain. Pain (2002) 96 129-140.
245. Walker K., Medhurst S.J., Kidd B.L. et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain (2002) 100 219-229.
246. Mao-Ying Q.L., Ren D.H., Mi W.L., Liu Q., Wang Y.Q. Analgesic effects of electroacupuncture combined with Celebrex on rats with tibial cancer pain. Zhong Xi Yi Jie He Xue Bao (2008) 6 830-835.
247. Wacnik P.W., Kehl L.J., Trempe T.M., Ramnaraine M.L., Beitz A.J., Wilcox G.L. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain (2003) 101 175-186.
248. Zhao C., Wacnik P.W., Tall J.M. et al. Analgesic effects of a soy-containing diet in three murine bone cancer pain models. J. Pain (2004) 5 104-110.
249. Vecht C.J. Cancer pain: a neurological perspective. Curr. Opin. Neurol. (2000) 13 649-653.
250. Andoh T., Sugiyama K., Fujita M. et al. Pharmacological evaluation of morphine and non-opioid analgesic adjuvants in a mouse model of skin cancer pain. Biol. Pharm. Bull. (2008) 31 520-522.
251. Cornblath D.R., McArthur J.C. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology (1988) 38 794-796.
252. Oh S.B., Tran P.B., Gillard S.E., Hurley R.W., Hammond D.L., Miller R.J. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J. Neurosci. (2001) 21 5027-5035.
253. Melli G., Keswani S.C., Fischer A., Chen W., Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain (2006) 129 1330-1338.
254. Herzberg U., Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J. Neuroimmunol. (2001) 116 29-39.
255. Wallace V.C., Blackbeard J., Pheby T. et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain (2007) 133 47-63.
256. Kennedy P.G., Grinfeld E., Gow J.W. Latent Varicella-zoster virus in human dorsal root ganglia. Virol (1999) 258 451-454.
257. Kennedy P.G. Key issues in varicella-zoster virus latency. J. Neurovirol. (2002) 8 80-84.
258. Dworkin R.H., Portenoy R.K. Proposed classification of herpes zoster pain. Lancet (1994) 343 1648.
259. Sadzot-Delvaux C., Debrus S., Nikkels A., Piette J., Rentier B. Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology (1995) 12(Suppl. 8) S18-S20.
260. Sadzot-Delvaux C., Merville-Louis M.P., Delrée P. et al. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J. Neurosci. Res. (1990) 26 83-89.
261. Fleetwood-Walker S.M., Quinn J.P., Wallace C. et al. Behavioural changes in the rat following infection with varicella-zoster virus. J. Gen. Virol. (1999) 80 2433-2436.
262. Dalziel R.G., Bingham S., Sutton D. et al. Allodynia in rats infected with varicella zoster virus - a small animal model for post-herpetic neuralgia. Brain Res. Brain Res. Rev. (2004) 46 234-242.
263. Hasnie F.S., Breuer J., Parker S. et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience (2007) 144 1495-1508.
264. Krohel G.B., Richardson J.R., Farrell D.F. Herpes simplex neuropathy. Neurology (1976) 26 596-597.
265. Takasaki I., Andoh T., Nitta M. et al. Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. Jpn. J. Pharmacol. (2000) 83 319-326.
266. Takasaki I., Andoh T., Shiraki K., Kuraishi Y. Allodynia and hyperalgesia induced by herpes simplex virus type-1 infection in mice. Pain (2000) 86 95-101.
267. Pan H.L., Khan G.M., Alloway K.D., Chen S.R. Resiniferatoxin induces paradoxical changes in thermal and mechanical sensitivities in rats: mechanism of action. J. Neurosci. (2003) 23 2911-2919.
268. Chen S.R., Pan H.L. Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia. Brain Res. (2005) 25 1042-1108.
269. Dina O.A., Barletta J., Chen X. et al. Key role for the epsilon isoform of protein kinase C in painful alcoholic neuropathy in the rat. J. Neurosci. (2000) 20 8614-8619.
270. Dina O.A., Messing R.O., Levine J.D. Ethanol withdrawal induces hyperalgesia mediated by PKCepsilon. Eur. J. Neurosci. (2006) 24 197-204.
271. Lieber C.S., DeCarli L.M., Sorrell M.F. Experimental methods of ethanol administration. Hepatology (1989) 10 501-510.
272. Narita M., Miyoshi K., Narita M., Suzuki T. Involvement of microglia in the ethanol-induced neuropathic pain-like state in the rat. Neurosci. Lett. (2007) 414 21-25.
273. Miyoshi K., Narita M., Narita M., Suzuki T. Involvement of mGluR5 in the ethanol-induced neuropathic pain-like state in the rat. Neurosci. Lett. (2006) 410 105-109.
274. Ammendola A., Gemini D., Iannaccone S. et al. Gender and peripheral neuropathy in chronic alcoholism: a clinical-electroneurographic study. Alcohol Alcohol. (2000) 35 368-371.
275. Foca F.J. Motor and sensory neuropathy secondary to excessive pyridoxine ingestion. Arch. Phys. Med. Rehabil. (1985) 66 634-636.
276. Hoover D.M., Carlton W.W., Henrikson C.K. Ultrastructural lesions of pyridoxine toxicity in beagle dogs. Vet. Pathol. (1981) 18 769-777.
277. Krinke G., Schaumburg H.H., Spencer P.S., Suter J., Thomann P., Hess R. Pyridoxine mega-vitaminosis produces degeneration of peripheral sensory neurons (sensory neuropathy) in the dog. Neurotoxicology (1980) 2 13-24.
278. Schaeppi U., Krinke G. Pyridoxine neuropathy: correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6. Agents Actions (1982) 12 575-582.
279. Chung J.Y., Choi J.H., Hwang C.Y., Youn H.Y. Pyridoxine induced neuropathy by subcutaneous administration in dogs. J. Vet. Sci. (2008) 9 127-131.
280. Krinke G., Naylor D.C., Skorpil V. Pyridoxine megavitaminosis: an analysis of the early changes induced with massive doses of vitamin B6 in rat primary sensory neurons. J. Neuropathol. Exp. Neurol. (1985) 44 117-129.
281. Windebank A.J., Low P.A., Blexrud M.D., Schmelzer J.D., Schaumburg H.H. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology (1985) 35 1617-1622.
282. Krinke G.J., Fitzgerald R.E. The pattern of pyridoxine-induced lesion: difference between the high and the low toxic level. Toxicology (1988) 49 171-178.
283. Xu Y., Sladky J.T., Brown M.J. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology (1989) 39 1077-1083.
284. Perry T.A., Weerasuriya A., Mouton P.R., Holloway H.W., Greig N.H. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp. Neurol. (2004) 190 133-144.
285. Kitt C.A., Gruber K., Davis M., Woolf C.J., Levine J.D. Trigeminal neuralgia: opportunities for research and treatment. Pain (2000) 85 3-7.
286. Love S., Gradidge T., Coakham H.B. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol. Appl. Neurobiol. (2001) 27 238-244.
287. Osterberg A., Boivie J., Thuomas K.A. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur. J. Pain (2005) 9 531-542.
288. Ahn D.K., Lim E.J., Kim B.C. et al. Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats. Eup. J. Pain (2008) 13 568-575. (doi: ), In press.
289. Yang G.Y., Lee M.K., Bae Y.C., Ahn D.K. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry (2009) 33 589-595.
290. Hanowell S.T., Kennedy S.F. Phantom tongue pain and causalgia: case presentation and treatment. Anesth. Analg. (1979) 58 436-438.
291. Imamura Y., Kawamoto H., Nakanishi O. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Exp. Brain Res. (1997) 116 97-103.
292. Alvarez P., Dieb W., Hafidi A., Voisin D.L., Dallel R. Insular cortex representation of dynamic mechanical allodynia in trigeminal neuropathic rats. Neurobiol. Dis. (2009) 33 89-95.
293. Eisenberg E., Vos B.P., Strassman A.M. The peripheral antinociceptive effect of morphine in a rat model of facial pain. Neuroscience (1996) 72 519-525.
294. Roveroni R.C., Parada C.A., Veiga M.C.F.A., Tambeli C.H. Development of a behavioral modelo of TMJ pain in rats: the TMJ formalin test. Pain (2001) 94 185-191.
295. Henry J.L. Future basic science directions into mechanisms of neuropathic pain. J. Orofac. Pain (2004) 18 306-310.
296. Ng C.H., Ong W.Y. Increased expression of gamma-aminobutyric acid transporters GAT-1 and GAT-3 in the spinal trigeminal nucleus after facial carrageenan injections. Pain (2001) 92 29-40.
297. Vahidy W.H., Ong W.Y., Farooqui A.A., Yeo J.F. Effects of intracerebroventricular injections of free fatty acids, lysophospholipids, or platelet activating factor in a mouse model of orofacial pain. Exp. Brain Res. (2006) 174 781-785.
298. Ro J.Y. Bite force measurement in awake rats: a behavioral model for persistent orofacial muscle pain and hyperalgesia. J. Orofac. Pain (2005) 19 159-167.
299. Costa L.G., Deng H., Callernan C.J., Bergmark E. Evaluation of the neurotoxicity of glycidamide, an epoxidemetabolite of acrylamide: behavioral, neurochemical and morphological studies. Toxicology, (1995) 98 151-161.
300. Stadler R.H., Blank I., Varga N. et al. Acrylamide from Maillard reaction products. Nature (2002) 419 449-450.
301. Rosen J., Hellenas K.E. Analysis of acrylamide in cooked foods by liquid chromatography tandem mass spectrometry. Analyst (2002) 127 880-882.
302. Gold B.G., Voda J., Yu X., Gordon H. The immunosuppressant FK506 elicits a neuronal heat shock response and protects against acrylamide neuropathy. Exp. Neurol. (2004) 187 160-170.
303. Li S.X., Cui N., Zhang C.L., Zhaoc X.L., Yu S.F., Xie K.Q. Effect of subchronic exposure to acrylamide induced on the expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology (2006) 217 46-53.